Pfizer has suspended worldwide clinical trials of its investigational pain drug, tanezumab, for osteoarthritis at the request of the US FDA after some patients receiving the drug experienced a worsening of their osteoarthritis that led to joint replacement. Trials for this population had reached the Phase III stage.
The drug is also in Phase II/III development for chronic low back pain and Phase II for cancer pain, interstitial...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
